Skip to Content
UW Health SMPH
American Family Children's Hospital
SHARE TEXT

Hydrazine Sulfate (PDQ®): Complementary and alternative medicine - Patient Information [NCI]

This information is produced and provided by the National Cancer Institute (NCI). The information in this topic may have changed since it was written. For the most current information, contact the National Cancer Institute via the Internet web site at http://cancer.gov or call 1-800-4-CANCER.

Hydrazine Sulfate

Overview

  • Hydrazine sulfate is a chemical compound that has been studied as a treatment for cancer and certain side effects caused by cancer (see Question 1).
  • Hydrazine sulfate may block the tumor from taking in glucose, which is a type of sugar that tumor cells need to grow (see Question 3).
  • In randomized clinical trials (a type of research study), hydrazine sulfate did not make tumors shrink or go away. In some randomized trials, however, hydrazine sulfate was reported to be helpful in treating anorexia and cachexia caused by cancer. (See Question 6.)
  • Hydrazine sulfate is sold as a dietary supplement in the United States. The US Food and Drug Administration has not approved the use of hydrazine sulfate as a cancer treatment, except in clinical trials (see Question 8).

Questions and Answers About Hydrazine Sulfate

What is hydrazine sulfate?

Hydrazine sulfate is a compound that has been studied as a treatment for cancer and for cancer-related anorexia (loss of appetite) and cachexia (loss of muscle mass and body weight).

What is the history of the discovery and use of hydrazine sulfate as a complementary or alternative treatment for cancer?

It has been known since the early 1900s that hydrazine compounds are toxic to animals and to humans. More than 400 hydrazine-related compounds have been tested for their ability to kill cancer cells. One of these compounds, procarbazine, has been used to treat Hodgkin disease, melanoma, and lung cancer since the 1960s.

In view of procarbazine's anticancer activity, hydrazine sulfate (a compound similar to procarbazine) was studied for its effectiveness in fighting cancer beginning in the 1970s. Studies of hydrazine sulfate as a treatment for cancer-related cachexia also began during this time.

Hydrazine compounds have also been used to make rocket fuel, as herbicides (chemicals that kill plants), and as chemical agents in boiler and cooling-tower water systems. Many scientists consider hydrazine sulfate and other similar substances to be cancer-causing agents and are concerned about the safety of using these compounds.

What is the theory behind the claim that hydrazine sulfate is useful in treating cancer?

Two theories have been suggested to explain how hydrazine sulfate acts against cancer and cachexia:

  • Hydrazine sulfate may prevent the body from making sugar that cancer cells need to grow. It has been suggested that cachexia occurs because the cancer is using too much of the body's sugar, preventing healthy cells from getting what they need to live. This causes tissues to die and muscle to waste away, and the patient loses weight.
  • Hydrazine sulfate may block tumor necrosis factor-alpha (TNF-alpha). This is a substance made by the body's white blood cells to fight infection and tissue damage. High levels of TNF-alpha have been found in cancer patients. These high levels of TNF-alpha may cause loss of appetite, tiredness, and the breakdown of muscle tissue. As muscle breaks down, it makes sugar that the cancer cells use to grow. Blocking the TNF-alpha might stop tumor growth and prevent cachexia.
How is hydrazine sulfate administered?

Hydrazine sulfate is taken by mouth in pills or capsules. There is no standard dose or length of treatment time.

Have any preclinical (laboratory or animal) studies been conducted using hydrazine sulfate?

Research in a laboratory or using animals is done to find out if a drug, procedure, or treatment is likely to be safe and useful in humans. These preclinical studies are done before any testing in humans is begun. The following has been learned from preclinical studies of hydrazine sulfate:

  • In most studies with rats, mice, and hamsters, hydrazine sulfate caused an increase in lung, liver, and breast cancers.
  • When used alone against certain types of cancer (including melanoma, leukemia, bladder, breast, and prostate), hydrazine sulfate slowed tumor growth in some animal studies and showed no effect in others. In cases where tumor growth was slowed the most, the animals lost large amounts of weight. This finding does not support the proposed use of hydrazine sulfate to treat cachexia caused by cancer.
  • When hydrazine sulfate was combined with an anticancer drug, it seemed to improve the anticancer effects in rats and mice. When hydrazine sulfate was combined with an anticancer drug that affects the way cells use sugar, however, it helped in some studies and did not help in others.
  • Preclinical studies by the National Cancer Institute (NCI) found that hydrazine sulfate showed no anticancer activity except in one type of cancer in rats. The NCI decided not to continue studying the compound as a treatment for cancer. Studies of hydrazine sulfate as a treatment for cancer-related anorexia and cachexia continued.

For more information on the preclinical studies, see the PDQ health professional version of Hydrazine Sulfate.

Have any clinical trials (research studies with people) of hydrazine sulfate been conducted?

Clinical trials are a type of research study that tests how well new drugs or other treatments work in people. There have been many studies of hydrazine sulfate in patients with advanced cancer. Researchers looked at the following:

  • Tumor response and/or survival among patients with various types of cancer.
  • Changes in body weight.
  • Quality of life.
  • Changes in nutritional status and metabolism (chemical changes that take place in cells and make energy needed for life).

Clinical trials of hydrazine sulfate have reported the following:

  • In the mid 1970s, clinical trials by a drug company found that a small number of patients who were treated with hydrazine sulfate for advanced cancer reported having a better appetite, losing less weight, feeling stronger, or having less pain. In some patients, the tumor got smaller or did not grow, or there was improvement in a cancer-related symptom. These clinical trials do not prove that hydrazine sulfate is effective for advanced cancer, however, because of weaknesses in study design. There was no control group (a group of patients who did not receive hydrazine sulfate) and half of the patients in the trial could not be counted in the results for reasons that include missing information, short treatment times, and receiving other treatment along with the hydrazine sulfate.
  • From the 1970s to the mid 1990s, Russian studies with hydrazine sulfate had mixed results. Little information was reported about the patients and their treatment and about the study design and methods. All of the patients in these studies also received standard treatment with surgery, chemotherapy, and/or radiation therapy. Therefore, it is not known if results were caused by hydrazine sulfate or one of the standard treatments, or both.
  • Clinical studies funded by the NCI in the 1970s found that hydrazine sulfate did not cause tumors to shrink or go away. Some patients reported small improvements in appetite, pain, and weight, but they did not last. These studies did not include control groups.
  • Four randomized controlled trials were done in the 1990s. A randomized trial is a study in which the patients are assigned by chance to separate groups to compare different treatments; neither the researchers nor the patients can choose which group. These trials compared hydrazine sulfate with a placebo (an inactive substance that looks like the treatment being tested). The results showed that hydrazine sulfate was not effective in treating cancer. In some cases, it was found to be harmful.
    • In three of the trials, lung cancer patients received either hydrazine sulfate or a placebo, along with anticancer drugs. The patients who received hydrazine sulfate did not live longer or have their tumors shrink any more than the placebo group. In one of the studies, patients who took hydrazine sulfate showed better nutritional status than patients in the placebo group, although the increase in body weight was small. In another of the studies, patients who received hydrazine sulfate had a worse quality of life than patients who received the same anticancer drugs plus the placebo. [1]
    • A fourth trial found that patients with colorectal cancer who received only hydrazine sulfate lived for a shorter time than patients who received only a placebo.
  • Four other randomized controlled trials studied the effects of hydrazine sulfate on nutritional status and metabolism. The studies showed some benefit from hydrazine sulfate.
    • In 2 of the studies[2], patients receiving hydrazine sulfate showed improvement in metabolism, appetite, and in either gaining weight or not losing weight.
    • In the other 2 clinical trials[3], lung and colon cancer patients receiving hydrazine sulfate had less cancer-related muscle wasting.
Have any side effects or risks been reported from hydrazine sulfate?

In general, the reported side effects of hydrazine sulfate treatment have been mild to moderate. Most side effects are reported to end when treatment with hydrazine sulfate is stopped. Some animal studies, however, suggest that hydrazine sulfate may be highly toxic (harmful) when combined with either alcohol or barbiturates (drugs with sedative and hypnotic effects).

Most of the side effects caused by hydrazine sulfate have involved the nervous system and gastrointestinal tract. These side effects include the following:

  • Nausea and/or vomiting.
  • Dizziness.
  • Abnormal feelings in the arms and legs (such as burning or prickling).
  • Nerve inflammation.
  • Impaired fine motor function (such as trouble writing).
  • Dry skin and/or itching.
  • Being unable to sleep.
  • Abnormally low blood sugar.

One case of fatal liver and kidney failure and one case of severe injury to the brain have been linked to the use of hydrazine sulfate.

Is hydrazine sulfate approved by the U.S. Food and Drug Administration (FDA) for use as a cancer treatment in the United States?

The FDA has not approved hydrazine sulfate for use as a cancer treatment in the United States.

The FDA has approved the study of hydrazine sulfate in clinical trials. Information about ongoing clinical trials can be found on the NCI Web site.

Hydrazine sulfate is sold in the United States as a dietary supplement, which is regulated as a food, not a drug. More information about dietary supplements can be found in the National Center for Complementary and Alternative Medicine online fact sheet, Using Dietary Supplements Wisely.

References:

1. Loprinzi CL, Goldberg RM, Su JQ, et al.: Placebo-controlled trial of hydrazine sulfate in patients with newly diagnosed non-small-cell lung cancer. J Clin Oncol 12 (6): 1126-9, 1994.
2. Chlebowski RT, Bulcavage L, Grosvenor M, et al.: Hydrazine sulfate in cancer patients with weight loss. A placebo-controlled clinical experience. Cancer 59 (3): 406-10, 1987.
3. Tayek JA, Heber D, Chlebowski RT: Effect of hydrazine sulphate on whole-body protein breakdown measured by 14C-lysine metabolism in lung cancer patients. Lancet 2 (8553): 241-4, 1987.

Changes To This Summary (02 / 20 / 2013)

The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above.

Editorial changes were made to this summary.

About This PDQ Summary

About PDQ

Physician Data Query (PDQ) is the National Cancer Institute's (NCI's) comprehensive cancer information database. The PDQ database contains summaries of the latest published information on cancer prevention, detection, genetics, treatment, supportive care, and complementary and alternative medicine. Most summaries come in two versions. The health professional versions have detailed information written in technical language. The patient versions are written in easy-to-understand, nontechnical language. Both versions have cancer information that is accurate and up to date and most versions are also available in Spanish.

PDQ is a service of the NCI. The NCI is part of the National Institutes of Health (NIH). NIH is the federal government's center of biomedical research. The PDQ summaries are based on an independent review of the medical literature. They are not policy statements of the NCI or the NIH.

Purpose of This Summary

This PDQ cancer information summary has current information about the use of hydrazine sulfate in the treatment of people with cancer. It is meant to inform and help patients, families, and caregivers. It does not give formal guidelines or recommendations for making decisions about health care.

Reviewers and Updates

Editorial Boards write the PDQ cancer information summaries and keep them up to date. These Boards are made up of experts in cancer treatment and other specialties related to cancer. The summaries are reviewed regularly and changes are made when there is new information. The date on each summary ("Date Last Modified") is the date of the most recent change.

The information in this patient summary was taken from the health professional version, which is reviewed regularly and updated as needed, by the PDQ Cancer Complementary and Alternative Medicine Editorial Board.

Clinical Trial Information

A clinical trial is a study to answer a scientific question, such as whether one treatment is better than another. Trials are based on past studies and what has been learned in the laboratory. Each trial answers certain scientific questions in order to find new and better ways to help cancer patients. During treatment clinical trials, information is collected about the effects of a new treatment and how well it works. If a clinical trial shows that a new treatment is better than one currently being used, the new treatment may become "standard." Patients may want to think about taking part in a clinical trial. Some clinical trials are open only to patients who have not started treatment.

Clinical trials are listed in PDQ and can be found online at NCI's Web site. Many cancer doctors who take part in clinical trials are also listed in PDQ. For more information, call the Cancer Information Service 1-800-4-CANCER (1-800-422-6237).

Permission to Use This Summary

PDQ is a registered trademark. The content of PDQ documents can be used freely as text. It cannot be identified as an NCI PDQ cancer information summary unless the whole summary is shown and it is updated regularly. However, a user would be allowed to write a sentence such as "NCI's PDQ cancer information summary about breast cancer prevention states the risks in the following way: [include excerpt from the summary]."

The best way to cite this PDQ summary is:

National Cancer Institute: PDQ® Hydrazine Sulfate. Bethesda, MD: National Cancer Institute. Date last modified <MM/DD/YYYY>. Available at: http://www.cancer.gov/cancertopics/pdq/cam/hydrazinesulfate/patient. Accessed <MM/DD/YYYY>.

Images in this summary are used with permission of the author(s), artist, and/or publisher for use in the PDQ summaries only. If you want to use an image from a PDQ summary and you are not using the whole summary, you must get permission from the owner. It cannot be given by the National Cancer Institute. Information about using the images in this summary, along with many other images related to cancer can be found in Visuals Online. Visuals Online is a collection of more than 2,000 scientific images.

Disclaimer

The information in these summaries should not be used to make decisions about insurance reimbursement. More information on insurance coverage is available on Cancer.gov on the Coping with Cancer: Financial, Insurance, and Legal Information page.

Contact Us

More information about contacting us or receiving help with the Cancer.gov Web site can be found on our Contact Us for Help page. Questions can also be submitted to Cancer.gov through the Web site's Contact Form.

General CAM Information

Complementary and alternative medicine (CAM)—also referred to as integrative medicine—includes a broad range of healing philosophies, approaches, and therapies. A therapy is generally called complementary when it is used in addition to conventional treatments; it is often called alternative when it is used instead of conventional treatment. (Conventional treatments are those that are widely accepted and practiced by the mainstream medical community.) Depending on how they are used, some therapies can be considered either complementary or alternative. Complementary and alternative therapies are used in an effort to prevent illness, reduce stress, prevent or reduce side effects and symptoms, or control or cure disease.

Unlike conventional treatments for cancer, complementary and alternative therapies are often not covered by insurance companies. Patients should check with their insurance provider to find out about coverage for complementary and alternative therapies.

Cancer patients considering complementary and alternative therapies should discuss this decision with their doctor, nurse, or pharmacist as they would any therapeutic approach, because some complementary and alternative therapies may interfere with their standard treatment or may be harmful when used with conventional treatment.

Evaluation of CAM Approaches

It is important that the same rigorous scientific evaluation used to assess conventional approaches be used to evaluate CAM therapies. The National Cancer Institute (NCI) and the National Center for Complementary and Alternative Medicine (NCCAM) are sponsoring a number of clinical trials (research studies) at medical centers to evaluate CAM therapies for cancer.

Conventional approaches to cancer treatment have generally been studied for safety and effectiveness through a rigorous scientific process that includes clinical trials with large numbers of patients. Less is known about the safety and effectiveness of complementary and alternative methods. Few CAM therapies have undergone rigorous evaluation. A small number of CAM therapies originally considered to be purely alternative approaches are finding a place in cancer treatment—not as cures, but as complementary therapies that may help patients feel better and recover faster. One example is acupuncture. According to a panel of experts at a National Institutes of Health (NIH) Consensus Conference in November 1997, acupuncture has been found to be effective in the management of chemotherapy-associated nausea and vomiting and in controlling pain associated with surgery. In contrast, some approaches, such as the use of laetrile, have been studied and found ineffective or potentially harmful.

The NCI Best Case Series Program, which was started in 1991, is one way CAM approaches that are being used in practice are being investigated. The program is overseen by the NCI's Office of Cancer Complementary and Alternative Medicine (OCCAM). Health care professionals who offer alternative cancer therapies submit their patients' medical records and related materials to OCCAM. OCCAM conducts a critical review of the materials and develops follow-up research strategies for approaches deemed to warrant NCI-initiated research.

Questions to Ask Your Health Care Provider About CAM

When considering complementary and alternative therapies, patients should ask their health care provider the following questions:

  • What side effects can be expected?
  • What are the risks associated with this therapy?
  • Do the known benefits outweigh the risks?
  • What benefits can be expected from this therapy?
  • Will the therapy interfere with conventional treatment?
  • Is this therapy part of a clinical trial?
  • If so, who is sponsoring the trial?
  • Will the therapy be covered by health insurance?

To Learn More About CAM

National Center for Complementary and Alternative Medicine (NCCAM)

The National Center for Complementary and Alternative Medicine (NCCAM) at the National Institutes of Health (NIH) facilitates research and evaluation of complementary and alternative practices, and provides information about a variety of approaches to health professionals and the public.

NCCAM Clearinghouse
Post Office Box 7923 Gaithersburg, MD 20898–7923
Telephone: 1–888–644–6226 (toll free) 301–519–3153 (for International callers)
TTY (for deaf and hard of hearing callers): 1–866–464–3615
Fax: 1–866–464–3616
E-mail: info@nccam.nih.gov
Web site: http://nccam.nih.gov

CAM on PubMed

NCCAM and the NIH National Library of Medicine (NLM) jointly developed CAM on PubMed, a free and easy-to-use search tool for finding CAM-related journal citations. As a subset of the NLM's PubMed bibliographic database, CAM on PubMed features more than 230,000 references and abstracts for CAM-related articles from scientific journals. This database also provides links to the Web sites of over 1,800 journals, allowing users to view full-text articles. (A subscription or other fee may be required to access full-text articles.) CAM on PubMed is available through the NCCAM Web site. It can also be accessed through NLM PubMed bibliographic database by selecting the "Limits" tab and choosing "Complementary Medicine" as a subset.

Office of Cancer Complementary and Alternative Medicine

The NCI Office of Cancer Complementary and Alternative Medicine (OCCAM) coordinates the activities of the NCI in the area of complementary and alternative medicine (CAM). OCCAM supports CAM cancer research and provides information about cancer-related CAM to health providers and the general public via the NCI Web site.

National Cancer Institute (NCI) Cancer Information Service

U.S. residents may call the NCI Cancer Information Service toll free at 1-800-4-CANCER (1-800-422-6237) Monday through Friday from 8:00 am to 8:00 pm. A trained Cancer Information Specialist is available to answer your questions.

Food and Drug Administration

The Food and Drug Administration (FDA) regulates drugs and medical devices to ensure that they are safe and effective.

Food and Drug Administration
5600 Fishers Lane
Rockville, MD 20857
Telephone: 1–888–463–6332 (toll free)
Web site: http://www.fda.gov/

Federal Trade Commission

The Federal Trade Commission (FTC) enforces consumer protection laws. Publications available from the FTC include:

  • Who Cares: Sources of Information About Health Care Products and Services
  • Fraudulent Health Claims: Don't Be Fooled
Consumer Response Center
Federal Trade Commission
CRC-240
Washington, DC 20580
Telephone: 1-877-FTC-HELP (1-877-382-4357) (toll free)
TTY (for deaf and hearing impaired callers): 202-326-2502
Web site: http://www.ftc.gov/

Last Revised: 2013-02-20


If you want to know more about cancer and how it is treated, or if you wish to know about clinical trials for your type of cancer, you can call the NCI's Cancer Information Service at 1-800-422-6237, toll free. A trained information specialist can talk with you and answer your questions.


This information does not replace the advice of a doctor. Healthwise, Incorporated disclaims any warranty or liability for your use of this information. Your use of this information means that you agree to the Terms of Use. How this information was developed to help you make better health decisions.

Healthwise, Healthwise for every health decision, and the Healthwise logo are trademarks of Healthwise, Incorporated.